Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | MITF | O75030 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | CDC25A | P30304 | 2/20 | 0.61 |
| ▸ | CDC25B | P30305 | 2/20 | 0.61 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436501 | 0.84 | MAPT (0.71) | MAPTALDH1A1MITFHTTNPSR1 | |
| Bilawsone SCHEMBL3768549 | 0.84 | APAF1 (0.75) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| Bilawsone SCHEMBL30884954 | 0.84 | APAF1 (0.75) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL14773924 | 0.77 | ME2 (0.74) | MAPTALDH1A1MITFHTTNPSR1 | |
| SCHEMBL571557 | 0.77 | MAPT (1.00) | MAPTALDH1A1MITFHTTNPSR1 | |
| SCHEMBL29545010 | 0.77 | MAPT (1.00) | MAPTALDH1A1MITFHTTNPSR1 | |
| SCHEMBL9628178 | 0.77 | MAPT (1.00) | MAPTALDH1A1MITFHTTNPSR1 | |
| SCHEMBL26655868 | 0.75 | APAF1 (0.67) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL5191181 | 0.74 | ALDH1A1 (0.62) | MAPTALDH1A1MITFHTTNPSR1 | |
| SCHEMBL16745426 | 0.73 | APAF1 (0.58) | MAPTALDH1A1MITFHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180116977-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180116977-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180116977-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | KLK3, AR, PLK1 | MAPT 1003/4885ALDH1A1 347/4885MITF 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.